Strong Revenue and Earnings Growth
Consolidated revenues increased 10% year-over-year to $103 billion, with adjusted earnings per diluted share increasing 39% to $9.86. Three segments delivered double-digit adjusted operating profit growth.
Oncology and Multispecialty Segment Success
Revenues increased 32% to $12 billion, driven by strong provider and specialty distribution growth, including acquisitions. Operating profit increased 71% to $397 million.
Prescription Technology Solutions Growth
Revenues increased 9% to $1.4 billion, with operating profit rising 20% to $261 million due to increased demand for access solutions and prior authorization services.
Increased Earnings Guidance
Guidance for adjusted earnings per diluted share raised to $38.35 - $38.85, representing 16% to 18% growth over the prior year.
Successful Implementation of New Reporting Structure
Introduction of new reporting structure enhances transparency and aligns with strategic growth areas, particularly in oncology and biopharma services.